Ascentage Pharma names new Chief Business Officer and Chief Commercial Officer

Ascentage Pharma Group International announced on August 2, 2026 that it had appointed Faiçal Miyara, PhD, as Chief Business Officer, responsible for the company's global business development, and Jim Ziegler as Chief Commercial Officer, responsible for the commercialization of the company's products in the United States and other countries outside of China.¹ Both will report directly to Dr. Dajun Yang, Chairman and Chief Executive Officer of the Company.¹

Dr. Miyara has more than 20 years of experience in oncology-focused business development across leading global pharmaceutical and biotechnology companies.¹ Prior to joining Ascentage Pharma, he served as CBO and member of the executive team at IO Biotech; prior, he served as Vice President, head of global partnering Oncology, Search and evaluation and Venture Capitals' relationship at Ipsen.¹ Dr. Miyara spent five years at Pfizer Inc., where he co-initiated the company's New York-based Center for Therapeutic Innovation (CTI) and held senior R&D leadership roles, and five years at ImClone Systems and Eli Lilly and Company, where he contributed to the research, optimization, and clinical development of FDA-approved oncology biologics including Erbitux® (cetuximab) and Cyramza® (ramucirumab).¹

Mr. Ziegler is an accomplished biopharmaceutical executive with more than 25 years of commercial and operational leadership.¹ He brings deep commercial experience from established industry leaders, including Amgen and Gilead Sciences, and emerging biopharmaceutical companies, Iovance Biotherapeutics and Geron where he led their global commercial teams.¹ Before entering the biopharmaceutical industry, Mr. Ziegler served as an Armor Officer in the U.S. Army. He earned a B.S. from the United States Military Academy at West Point and an M.B.A. from the University of Chicago.¹

The company continues to advance its late-stage pipeline. It is currently conducting an FDA- and EMA-cleared registrational Phase III trial, called POLARIS-2, of olverembatinib for CML, as well as FDA- and EMA-cleared registrational Phase III trials for patients with newly diagnosed Ph+ ALL, called POLARIS-1, and SDH-deficient GIST patients, called POLARIS-3.¹ It is also running four global registrational Phase III trials of lisaftoclax: GLORA, combining lisaftoclax with BTK inhibitors in CLL/SLL patients previously treated with BTK inhibitors for more than 12 months with suboptimal response; GLORA-2 in newly diagnosed CLL/SLL; GLORA-3 in newly diagnosed, elderly and unfit AML patients; and GLORA-4 in newly diagnosed higher risk MDS.¹